Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3565-3571

  Morii, Takeshi ^a   Ohtsuka, Kouki ^a   Ohnishi, Hiroaki ^a   Mochizuki, Kazuo ^a   Satomi, Kazuhiko ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; Heat shock protein 27; Osteosarcoma; Zoledronic acid

Indexed keywords

ABC TRANSPORTER; DOXORUBICIN; HEAT SHOCK PROTEIN 27; MESSENGER RNA; SMALL INTERFERING RNA; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SUBPOPULATION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; GENE SILENCING; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOBLOTTING; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 77958568496     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D and Pazdur R: Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9: 2394-2399, 2003.
2. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F and Thurlimann B: Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432, 2008.
3. Susa M, Morii T, Yabe H, Horiuchi K, Toyama Y, Weissbach L, Hornicek FJ and Morioka H: Alendronate inhibits growth of high-grade chondrosarcoma cells. Anticancer Res 29: 1879-1888, 2009.
4. Green JR: Antitumor effects of bisphosphonates. Cancer 97: 840-847, 2003.
5. Yuasa T, Kimura S, Ashihara E, Habuchi T and Maekawa T: Zoledronic acid - a multiplicity of anticancer action. Curr Med Chem 14: 2126-2135, 2007. (Pubitemid 47578153)
6. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
7. Dass CR and Choong PF: Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 6: 3263-3270, 2007.
8. Ory B, Blanchard F, Battaglia S, Gouin F, Redini F and Heymann D: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71: 333-343, 2007.
9. Evdokiou A, Labrinidis A, Bouralexis S, Hay S and Findlay DM: Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33: 216-228, 2003. (Pubitemid 37117133)
10. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini F: Enhanced tumour regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37: 74-86, 2005.
11. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
12. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 78A: 366-375, 1996. (Pubitemid 126528446)
13. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML and Meyers P: Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 25: 2057-2062, 2007.
14. Rajkumar T and Yamuna M: Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs 19: 257-265, 2008.
15. Kars MD, Iseri OD, Ural AU and Gunduz U: In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 27: 4031-4037, 2007.
16. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Redini F, Rogers M and Heymann D: Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 12: 928-941, 2008.
17. McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW and Landing BH: Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27: 397-402, 1971.
18. Morioka H, Morii T, Vogel T, Hornicek FJ and Weissbach L: Interaction of plasminogen-related protein B with endothelial and smooth muscle cells in vitro. Exp Cell Res 287: 166-177, 2003. (Pubitemid 36683211)
19. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, Ikeda Y and Kizaki M: Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/CHK1/CDC25 pathway in human osteosarcoma cells. Int J Oncol 31: 285-291, 2007.
20. Mehlen P, Schulze-Osthoff K and Arrigo AP: Small stress proteins as novel regulators of apoptosis. Heat-shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J Biol Chem 271: 16510-16514, 1996.
21. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF and Soliani P: Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol 78: 133-141, 2009.
22. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterluty H, Scotlandi K, Kotz R, Micksche M and Berger W: Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24: 1145-1152, 2006.
23. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T and Fushiki S: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 96: 255-261, 2007.
24. Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, Schwartz JH and Borkan SC: Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 283: 12305-12313, 2008.
25. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM and Evdokiou A: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 15: 3451-3461, 2009.
26. Spugnini EP, Vincenzi B, Caruso G, Baldi A, Citro G, Santini D and Tonini G: Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Pract 50: 44-46, 2009.
27. Duan Z, Choy E, Jimeno JM, Cuevas CD, Mankin HJ and Hornicek FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63: 1121-1129, 2008.
28. Shao L, Kasanov J, Hornicek FJ, Morii T, Fondren G and Weissbach L: Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 66: 2381-2395, 2003. (Pubitemid 37460995)
29. Russell RG and Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106, 1999.
30. Concannon CG, Gorman AM and Samali A: On the role of Hsp27 in regulating apoptosis. Apoptosis 8: 61-70, 2003.
31. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000
32. Rondeaux P, Horman S, Galand P and Mairesse N: Effects of antisense Hsp27 gene expression in osteosarcoma cells. In Vitro Cell Dev Biol Anim 33: 655-658, 1997.
33. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T and Machinami R: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat-shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79: 2336-2344, 1997. (Pubitemid 27251016)
34. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG and Yoo BC: Up-regulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing HER2 protein stability. BMC Cancer 8: 286, 2008.
35. Tsuruta M, Nishibori H, Hasegawa H, Ishii Y, Endo T, Kubota T, Kitajima M and Kitagawa Y: Heat-shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncol Rep 20: 1165-1172, 2008.
36. Shi P, Wang MM, Jiang LY, Liu HT and Sun JZ: Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat-shock protein 27 overexpression. Chin Med J (Engl) 121: 1975-1979, 2008.